Analysed LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) News Sources
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships
10-04-2026
yahoo.com
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year
02-04-2026
yahoo.com
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
01-04-2026
yahoo.com
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
31-03-2026
yahoo.com
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
31-03-2026
yahoo.com
Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership
27-03-2026
yahoo.com
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming
25-03-2026
yahoo.com
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
23-03-2026
yahoo.com
What is the current price of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ)?
The current price of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) is $3.04.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) absolute price change since previous trading day?
The absolute price change of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) since the previous trading day is $0.14.
LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) percentage price change since previous trading day?
The percentage price change of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) since the previous trading day is 4.8276%.
What is the most recent average sentiment score for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ)?
The most recent average sentiment score for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ)?
The most recent sentiment for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ) is .
SEC-8K** Filing Available For LIXTE BIOTECHNOLOGY HOLDINGS (LIXT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.